Advertisement
Journal Home
Search for

Volume 103, Issue 11, Pages 1495-1499 (1 June 2009)


View previous. 5 of 34 View next.

Usefulness of Abnormal Heart Rate Turbulence to Predict Cardiovascular Mortality in High-Risk Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction (from the EPHESUS Study)

Phyllis K. Stein, PhDaCorresponding Author Informationemail address, Prakash Deedwania, MDb

Received 17 November 2008; received in revised form 31 January 2009; accepted 31 January 2009. published online 10 April 2009.

Heart rate turbulence (HRT) is a promising marker for risk of mortality after acute myocardial infarction (AMI). We investigated HRT for risk stratification in high-risk patients after MI. HRT from 24-hour Holter monitoring in 481 hospitalized patients after AMI with heart failure and/or diabetes with left ventricular dysfunction before randomization in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Over a 1-year follow-up, 55 died, 49 of cardiovascular causes. HRT onset (TO) and slope (TS) were calculated using previous and cohort-optimized cutpoints and their independent contribution to risk of cardiovascular death determined. Models were tested with <5 ventricular premature complexes (PVCs) categorized as normal (n = 452) and with <5 VPCs excluded (n = 342). In EPHESUS, optimal cutpoints were TS ≤3.0 and TO ≥0.0. The strongest model for predicting cardiovascular mortality used EPHESUS cutpoints excluding subjects with <5 VPCs. On 3-category HRT model multivariate analysis (TS and TO normal, TS or TO abnormal, TS and TO abnormal), both TS and TO abnormal (relative risk 3.64, 95% confidence interval 1.55 to 8.55, p = 0.003) and left ventricular ejection fraction ≤30% (relative risk 1.97, 95% confidence interval 1.04 to 3.73, p = 0.037) independently predicted cardiovascular death. In conclusion, HRT is an independent predictor of cardiovascular death in a high-risk population after AMI, with a possibly higher optimal cutpoint for HRT slope than previously reported.

a Washington University School of Medicine, St. Louis, Missouri

b UCSF Fresno/VACCHS, Fresno, California

Corresponding Author InformationCorresponding author: Tel: 314-286-1350; fax: 314-286-1394

 This study supported in part by a grant from Pfizer Pharmaceuticals, New York, New York.

PII: S0002-9149(09)00530-X

doi:10.1016/j.amjcard.2009.01.362


View previous. 5 of 34 View next.